Compare Neurocrine Biosciences Inc (NBIX) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NetEase Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while NetEase Inc trades at $116.51 (market cap $76.85B). The key difference: NetEase Inc is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and NetEase Inc pays a 2.45% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NTES | |
|---|---|---|
Market Cap | $15.77B | $76.85B |
Sector | Health | Media |
52-Week High | $185.50 | $159.34 |
52-Week Low | $123.10 | $109.26 |
Enterprise Value | $15.78B | $52.59B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
NTES trades at $119.45, up 0.13% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $1.77, missing expectations of $2.32, though revenue grew 8% year-over-year to $4.4 billion. Strong fundamentals include a 27.88% net income margin and $137.58 billion in cash, supporting dividend growth and AI investments.
Outlook is mixed: analyst consensus is strongly bullish (82% buy ratings), citing undervaluation and international expansion potential, but near-term risks include earnings volatility and competitive pressures in gaming. The stock offers value at a P/E of 15.93, yet technical weakness suggests cautious entry points near support at $117.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
